share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

SEC announcement ·  Jan 18 00:00
Summary by Moomoo AI
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on January 16, 2024, involving the sale of 20,000 shares of common stock. The shares were sold at a price of $62.5029 per share, resulting in a total transaction value of $1,250,058. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at $19.12 each. Following the transactions, Kulkarni's direct holdings in the company amount to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on January 16, 2024, involving the sale of 20,000 shares of common stock. The shares were sold at a price of $62.5029 per share, resulting in a total transaction value of $1,250,058. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at $19.12 each. Following the transactions, Kulkarni's direct holdings in the company amount to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more